It's been just reported that there's a new discovery of an innovative immune cell receptor that could pave the way for a new type of T-cell cancer therapy.
The experts who made this massive discovery are highlighting that testing is still at a really early stage, but it's extremely promising.
That new immune cell carries a never-before-seen receptor which acts like a grappling hook, latching on to most human cancers, while ignoring healthy cells.
But the newly discovered T-cell will be able to differentiate between the two.
The work was led by Sewell's team from Cardiff University in the United Kingdom but also involved American, Australian and Danish researchers.
"Previously nobody believed this could be possible".
"It raises the prospect of a "one-size-fits-all" cancer treatment, a single type of T-cell that could be capable of destroying many different types of cancers across the population", Sewell said.
"We discovered that a population of T cells able to live exclusively within the human liver can switch on autophagy to maintain nutrient supply and renew organelles like mitochondria to maintain their fitness".
Researchers have screened thousands of existing drug molecules against cancer cell lines to discover nearly 50 compounds that combat the condition.
What's even more important is that it left normal, healthy tissues untouched. Professor Awen Gallimore, of the University's division of infection and immunity, and cancer immunology lead for the Wales Cancer Research Centre, said: "If this transformative new finding holds up, it will lay the foundation for a universal T-cell medicine, mitigating against the tremendous costs associated with the identification, generation and manufacture of personalised T-cells".
The study found that dozens of drugs-used to treat diabetes, osteoarthritis in dogs, or alcohol dependence-inhibited cancer cells in lab experiments.
Dr Corsello says that there's still a great deal of lab testing to be done before the drugs are ready for human trials, though Antabuse could potentially reach that point within a year or two.
The hope is that these modified cells would then be able to create the TCR which scans for cancerous cells and attacks them. "We just don't know yet". T-cell recognition of multiple cancers with and without the MR1 gene and other methods were used to confirm the mechanism by which these cancers were being targeted and destroyed.
But these enzymes are by no means the only thing that fuel cancer cells.
The findings, now published in the journal Nature Immunology, spell hope for a "universal cancer therapy" that could be used to target all cancers.
Scientists at Harvard, Massachusetts University of Technology and the Dana-Farber Cancer Institute have identified 49 existing drugs with potential to kill tumor cells.
One of the most groundbreaking recent advances in cancer treatment has been the development of CAR-T immunotherapy.